double-blind
Sponsors
Synairgen (United Kingdom), Syndax Pharmaceuticals, Inc., Ogeda S.A, Novartis, Hexal AG
Conditions
Advanced cancerRespiratory viral infections
Infections and InfestationsSteinLeventhal syndromeasthma
chronic lung inflammationinfection
reduced white blood cell count
Phase 2
Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Polycystic Ovarian Syndrome
Active, not recruitingNL-OMON43634
Start: 2015-11-30Target: 12Updated: 2024-02-28
A randomized, double-blind, repeat dose cross-over study
to assess the bronchodilator effects of once daily QVM149
following morning or evening dosing for 14 days compared
to placebo in patients with asthma
Active, not recruitingNL-OMON44320
Start: 2017-06-22Target: 20Updated: 2024-02-28
A Phase II study to understand the safety and effects of inhaled SNG001, the study medication, in patients who are mechanically ventilated due to a respiratory viral infection in the lungs
RecruitingISRCTN30482473
Start: 2025-03-31Target: 450Updated: 2025-02-24
Unknown Phase
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUNTEERS TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING SINGLE AND MULTIPLE DOSES OF SNDX-6352 OR PLACEBO ADMINISTERED BY INTRAVENOUS (I.V.) INFUSION
Active, not recruitingNL-OMON42865
Start: 2016-10-20Target: 52Updated: 2024-02-28
A randomized, double-blind, three-way crossover study to compare the pharmacokinetics, pharmacodynamics and safety of a single 6 mg subcutaneous administration of the
proposed biosimilar product LA-EP2006, Neulasta® US and Neulasta® EU in healthy subjects
Active, not recruitingNL-OMON45253
Start: 2017-04-14Target: 136Updated: 2024-02-28